| Literature DB >> 28540152 |
Jiachen Peng1,2,3, Youliang Ren2,3, Wenbin He2,3, Zhengdao Li2,3, Jin Yang2,3, Yi Liu2,3, Zhonghui Zheng4,5, Stephen L Kates2,5,6, Edward M Schwarz2,5, Chao Xie2,5, Youjia Xu1.
Abstract
Objective To determine the epidemiological, clinical and microbiological characteristics, of patients with post-traumatic osteomyelitis of extremity fractures, and provide evidence-based guidelines for early diagnosis and treatment, including empiric antibiotic therapy. Methods Human subject research was performed using institutional review board approved protocols. A retrospective chart review was conducted on 5,368 patients diagnosed with extremity traumatic fractures from January 1, 2012 to December 31, 2015, to identify osteomyelitis patients. Records from the Microbiology Department were reviewed, and patients with a positive wound culture, or bone biopsy culture, were selected for the study. Microbial suceptability was determined by the M-100-S22 protocol (Clinical & Laboratory Standards Institute® (CLSI) 2012 USA). Additional clinical information, including data on patients' baseline epidemiological, clinical, and microbiological records was collected from all available charts, and reviewed using a designed protocol. Results 84 (1.56%) patients were diagnosed with osteomyelitis based on a positive culture result. The most prevalent comorbidities in these patients were compartment syndrome, diabetes and hypertension. The most commonly involved infected site was the tibia-fibula (47.62%). 66 (78.57%) of these cases were monomicrobial, and 18 cases (21.43%) were polymicrobial. The infections were predominantly caused by Gram-positive bacteria (56, 53.85%). The most common Gram-positive bacteria were Staphylococcus aureus (39 cases, 37.50%) and S. epidermidis (6 cases, 5.77%), which were sensitive to ampicillin, synercid/ dalfopristin, linezolid, tigecycline, macrodantin, and vancomycin. S. aureus was the most common pathogen in both monomicrobial and polymicrobial cases. All 17 cases of MRSA infection were sensitive to Imezolid, ampicillin, synercid/ dalfopristin, linezolid, tigecycline, furadantin, piperacillin/yaz, rifampicin, and vancomycin, respectively. The most common Gram-negative bacteria were E. coli (16 cases, 15.38%) and Enterobacter cloacae (11 cases, 10.58%), which were sensitive to thienamycin. Conclusions In this study, the overall rate of post-traumatic osteomyelitis of limb fractures (1.56%) is lower than the national average rate (2.6-7.8%), for major medical centers in China. The main medical comorbidities were compartment syndrome, diabetes mellitus and hypertension. The most common infection was monomicrobial in lower extremities. S. aureus was the most common pathogen, which presented in 39 (37.50%) cases, and 17 of these (43.59%) were caused by MRSA. These findings can guide empiric antibiotic therapy in Southwest China for osteomyelitis in patients with traumatic limb fractures.Entities:
Keywords: Antibiotic resistance, Regional characteristics.; Limb fracture; Methicillin-resistant Staphylococcus aureus (MRSA); Osteomyelitis
Year: 2017 PMID: 28540152 PMCID: PMC5441147 DOI: 10.7150/jbji.20002
Source DB: PubMed Journal: J Bone Jt Infect ISSN: 2206-3552
Medical comorbidities in patients with osteomyelitis
| Comorbidity | n |
|---|---|
| Osteofascial compartment syndrome | 4 |
| Diabetes | 4 |
| Hypertension | 3 |
| Hpatic dysfunction | 2 |
| Craniocerebral trauma | 2 |
| Closed thoracic trauma | 2 |
| Osteoporosis | 2 |
| Hyperuricemia | 1 |
| Hypoproteinemia | 1 |
| Hyperkalemia | 1 |
The Distribution and percentage of affected sites
| Infection site | Single infection (%) | Mixed infection (%) | Total (%) |
|---|---|---|---|
| Tibia and Fibula | 32 (38.10) | 8 (9.52)** | 40 (47.62) |
| Femur | 13 (15.48) | 7 (8.33)** | 20 (23.81) |
| Radius and Ulna | 9 (10.71) | 2(2.38)** | 11 (13.10) |
| Humerus | 5 (5.95) | — | 5 (5.95) |
| Patella | 5 (5.95) | — | 5 (5.95) |
| Calcaneus | 2 (2.38) | 1 (1.19)** | 3 (3.57) |
Notes: The superscript ** are mix infection cases which the detail is listed in table 4 Mix infection: Sites and pathogenic bacteria.
The proportion and cases of the Gram-positive/negative bacteria
| Pathogenic bacteria | Isolate | Proportion (%) |
|---|---|---|
| Staphylococcus aureus ** | 39 | 37.5 |
| Staphylococcus epidermidis** | 6 | 5.77 |
| Enterococcus avium ** | 2 | 1.92 |
| Staphylococcus simulans | 1 | 0.96 |
| Streptococcus milleri ** | 1 | 0.96 |
| Staphylococcus aureus subspecies** | 1 | 0.96 |
| Staphylococcus hominis** | 1 | 0.96 |
| Enterococcus faecalis ** | 5 | 4.81 |
| Escherichia coli** | 16 | 15.38 |
| Enterobacter cloacae** | 11 | 10.58 |
| Klebsiella pneumoniae** | 4 | 3.85 |
| Pseudomonas aeruginosa** | 4 | 3.85 |
| Citrobacter koseri | 2 | 1.92 |
| Serratia marcescens | 1 | 0.96 |
| Morganella morganii | 2 | 1.92 |
| Baumann acinetobacter** | 6 | 5.77 |
| Klebsiella oxytoca ** | 1 | 0.96 |
| Basillus ** | 1 | 0.96 |
| Total | 104 | 100 |
Note: The superscript ** are mix infection cases which the detail is listed in table 4 Mix infection: Sites and pathogenic bacteria.
Mix infection: Sites and pathogenic bacteria
| Sites | Case No. | Pathogenic bacteria | ||
|---|---|---|---|---|
| A | B | C | ||
| Tibia and Fibula (44.4%) | 1 | S.aureus | Klebsiella pneumoniae | |
| 2 | S.aureus | Pseudomonas aeruginosa | ||
| 3 | S.aureus | Streptococcus epidermidis | S. Hominic | |
| 4 | S.aureus | Streptococcus milleri | ||
| 5 | S.aureus subspecies | Psiudomonas aeruginoso | ||
| 6 | S. epidermidis | Basillus | ||
| 7 | Enterobacter cloacae | Baumann acinetobacter | ||
| 8 | Enterobacter cloacae | Klebsiella oxytoca | ||
| Femur (38.9%) | 9 | S.aureus | Baumann acinetobacter | |
| 10 | S.aureus | Escherichia coli | Baumann acinetobacter | |
| 11 | S. epidermidis | Enterococcus faecali | ||
| 12 | Enterococcus avium | Escherichia coli | ||
| 13 | Enterococcus faecalis | Enterobacter cloacae | ||
| 14 | Eschrichia coli | Baumann acinetobacter | ||
| 15 | Eschrichia coli | Baumann acinetobacter | ||
| Radius and Ulnar (11.1%) | 16 | S.aureus | Enterobacter cloacae | |
| 17 | S.aureus | Pseudomonas aeruginosa | ||
| Calcaneus (5.60%) | 18 | Enterococcus faecalis | Escherichia coli | |
The rate of drug resistance of the main Gram-positive bacteria
| Antibiotics | S.aureus (n=39) | S. epidermidis (n=6) | |||
|---|---|---|---|---|---|
| Cases (n) | Drug resistance rate (%) | Cases (n) | Drug resistance rate (%) | ||
| Penicillin | 29 | 74.36 | 6 | 100 | |
| Erythrocin | 24 | 61.54 | 3 | 50 | |
| Lincomycin | 22 | 56.41 | 5 | 83.33 | |
| Tetracycline | 21 | 53.85 | 4 | 66.67 | |
| Oxacillin | 17 | 35.9 | 5 | 83.33 | |
| Cefoxitin | 17 | 35.9 | 3 | 50 | |
| Levofloxacin | 6 | 15.38 | 3 | 50 | |
| Inducible clindamycin | 6 | 15.38 | 2 | 33.33 | |
| Co-trimoxazole | 4 | 10.26 | 3 | 50 | |
| Ciprofloxacin | 4 | 10.26 | 2 | 33.33 | |
| Moxifloxacin | 2 | 5.13 | 1 | 16.67 | |
| Rifampicin | 1 | 2.56 | 2 | 33.33 | |
| Vancomycin | 0 | 0 | 0 | 0 | |
| Tigecycline | 0 | 0 | 0 | 0 | |
| Synercid/ Dalfopristin | 0 | 0 | 0 | 0 | |
| Macrodantin | 0 | 0 | 0 | 0 | |
| Linezolid | 0 | 0 | 0 | 0 | |
| Ampicillin | 0 | 0 | 0 | 0 | |
The rate of drug resistance of Staphylococcus aureus
| Antibiotics | MRSA(n=17) | MSSA(n=22) | |||
|---|---|---|---|---|---|
| Cases | Drug resistance rate (%) | Cases | Drug resistance rate (%) | ||
| Penicillin | 17 | 100 | 22 | 100 | |
| Erythrocin | 17 | 100 | 7 | 31.82 | |
| Cefoxitin | 17 | 100 | 0 | 0 | |
| Oxacillin | 17 | 100 | 0 | 0 | |
| Lincomycin | 16 | 94.12 | 6 | 27.27 | |
| Tetracycline | 9 | 52.94 | 13 | 59.09 | |
| Levofloxacin | 2 | 11.76 | 4 | 18.75 | |
| Ciprofloxacin | 2 | 11.76 | 2 | 9.09 | |
| Inducible clindamycin | 1 | 5.88 | 5 | 22.73 | |
| Co-trimoxazole | 1 | 5.88 | 3 | 13.64 | |
| Gentamicin | 1 | 5.88 | 3 | 13.64 | |
| Moxifloxacin | 1 | 5.88 | 1 | 4.55 | |
| Amoxicillin/Clavulanic acid | 1 | 5.88 | 0 | 0 | |
| Cefazolin | 1 | 5.88 | 0 | 0 | |
| Thiomycin | 1 | 5.88 | 0 | 0 | |
| Rifampicin | 0 | 0 | 1 | 4.55 | |
| Imezolid | 0 | 0 | 0 | 0 | |
| Ampicillin /sulbactam | 0 | 0 | 0 | 0 | |
| Synercid/ Dalfopristin | 0 | 0 | 0 | 0 | |
| Linezolid | 0 | 0 | 0 | 0 | |
| Tigecycline | 0 | 0 | 0 | 0 | |
| Furadantin | 0 | 0 | 0 | 0 | |
| Piperacillin/Tazo | 0 | 0 | 0 | 0 | |
| Vancomycin | 0 | 0 | 0 | 0 | |
The rate of drug resistance of the main Gram-negative bacteria
| Antibiotics | E. coli (n=16) | Enterobacter cloacae (n=11) | |||
|---|---|---|---|---|---|
| Cases | Drug resistance rate (%) | Cases | Drug resistance rate (%) | ||
| Ampicillin | 14 | 87.5 | 10 | 90.91 | |
| Cefazolin | 14 | 87.5 | 7 | 63.64 | |
| Sulbactam | 12 | 75 | 10 | 90.91 | |
| Ceftriaxone | 11 | 68.75 | 5 | 45.45 | |
| Levofloxacin | 11 | 68.75 | 4 | 36.36 | |
| Ciprofloxacin | 9 | 56.25 | 4 | 36.36 | |
| Co-trimoxazole | 9 | 56.25 | 3 | 27.27 | |
| ESBL | 9 | 56.25 | 2 | 18.18 | |
| Aztreonam | 6 | 37.5 | 5 | 45.45 | |
| Ceftazidime | 6 | 37.5 | 5 | 45.45 | |
| Gentamicin | 6 | 37.5 | 5 | 45.45 | |
| Cefepime | 5 | 31.25 | 4 | 36.36 | |
| Cefotetan | 1 | 6.25 | 8 | 72.73 | |
| Amoxicillin | 1 | 6.25 | 3 | 27.27 | |
| Nitrofurantoin | 0 | 0 | 6 | 54.55 | |
| Tobramycin | 0 | 0 | 5 | 45.45 | |
| Piperacillin | 0 | 0 | 4 | 36.36 | |
| Amikacin | 0 | 0 | 4 | 36.36 | |
| Erythrocin | 0 | 0 | 3 | 27.27 | |
| Piperacilin/Tazo | 0 | 0 | 3 | 27.27 | |
| Ertapenem | 0 | 0 | 2 | 18.18 | |
| Thienamycin | 0 | 0 | 0 | 0 | |